From: Efficacy and safety of moxifloxacin in community acquired pneumonia: a prospective, multicenter, observational study (CAPRIVI)
Duration (days)
Total N = 2152 (100.0%)
n
(%)
0
1840
(85.5)
1
107
(5.0)
2
55
(2.6)
3
46
(2.1)
4
32
(1.5)
5
36
(1.7)
6
34
(1.1)
Missing
12
(0.6)